Sanofi Sa · EURONEXT:SAN
Sanofi Sa — Nomura Healthcare Conference 2011
18 slides from Sanofi Sa's conference presentation, Jul 1, 2011
Slide 1: Nomura Healthcare Conference
Nomura Healthcare Conference Sebastien Martel Head of Investor Relations London, July 1st, 2011
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their und
Slide 3: Q1 2011 - Solid Underlying Sales Performance
3 Q1 2011 - Solid Underlying Sales Performance ● Q1 2011 sales reached Total Sales (€m)(3) €7,779m €7,898m €7,779m ● Q1 2010 sales included A/H1N1 €413m €413m of A/H1N1 vaccine (2) sales €7,107m €7,485m ● Excluding A/H1N1, Q1 2011 sales growth was: ● +0.1% at CER(1) Q1 2009 Q1 2010 Q1 2011 (1) Growt
Slide 4: Q1 2011 - Getting through the Patent Cliff
4 Q1 2011 - Getting through the Patent Cliff ● Q1 2011 sales of key Key Genericized Products Sales (€m) genericized products reduced by >€1bn vs. Q1 2009: €2,014m ● Lovenox® U.S. ● Plavix® Western EU €1,488m ● Taxotere® Western EU & U.S. ● Eloxatin® U.S.(1) €945m ● Ambien CR® U.S. ● Allegra® U.S. ●
Slide 5: Q1 2011 - Strong Performance from Growth Platforms
5 Q1 2011 - Strong Performance from Growth Platforms ● Sales from growth platforms Growth Platforms Sales (€m)(3) represented 59.2% of total sales in €4,607m Q1 2011 vs. 42.2% in Q1 2009 €4,262m A/H1N1 ● An increase of >€1.3bn vs. €413m Q1 2009 pro forma sales(2) €3,849m ● Excluding A/H1N1, our grow
Slide 6: Continued Effort to Control Costs in Q1 2011
6 Continued Effort to Control Costs in Q1 2011 Cost of Sales (%) R&D/Sales Ratio (%) SG&A/Sales Ratio (%) 30.4% 14.5% 27.6% 24.8% 14.1% 23.3% Q1 2010 Q2 201 0 Q3 2010 Q4 2010 Q1 2 011 Q1 2010 Q2 20 10 Q3 2010 Q4 2010 Q1 2 011 Q1 2010 Q2 2010 Q3 2010 Q4 2010 Q1 2011
Slide 7: Q1 2011 - Resilient EPS despite Generic Headwind
7 Q1 2011 - Resilient EPS despite Generic Headwind ● Q1 2011 Business EPS was Business EPS (€) €1.66 €1.86 ● €0.20 of Q1 2010 Business €0.20 €1.66 EPS was related to A/H1N1 €1.66 vaccine sales ● Excluding A/H1N1, Q1 2011 Business EPS was 6.0% lower at CER(1) Q1 2010 Q1 2011 (1) Growth is at CER (Con
Slide 8: Stable FCF despite Lack of A/H1N1 in Q1 2011 and Net Debt Free Status
Stable FCF despite Lack of A/H1N1 in Q1 2011 8 and Net Debt Free Status at End of Q1 2011 Net Cash from Net Debt Operating Acquisitions & Restructuring Net Debt Dec 31, 2010 Activities CapEx Licensing(2) Costs & Others(3) Mar 31, 2011 750 -340 250 ‐382 +16 -31 -250 +2,346 €m FCF -750 +2,006(1) Chang
Slide 9: Merial - A Fully Owned Consolidated Growth Platform
9 Merial - A Fully Owned Consolidated Growth Platform Key Brands ● #3 Animal Health player(1) with sales of €2bn(2) ● #1 in Companion Animals and Parasiticides(1) ● Double-digit growth in Emerging Markets ● High operating margin(3) ● Opportunity for synergies ● New innovative brands, geographic expa
Slide 10: Genzyme - A New Platform for Sustainable Growth with Near Term Value Drivers
Genzyme - A New Platform for Sustainable 10 Growth with Near Term Value Drivers ● Business EPS accretion expected already in 2011 ● Cost of financing <2% before tax in 2011 ● Integration progressing well ● Manufacturing recovery on-track ● Remediation plan submitted to FDA ● All fill & finish activi
Slide 11: Emerging Markets - Expanding our Leadership
11 Emerging Markets - Expanding our Leadership ● Q1 2011 sales in Emerging Q1 2011 Sales Breakdown Markets(1): €2,386m, +14.6% at CER excluding A/H1N1(2) Emerging RoW(3) Markets ● Emerging Markets sales exceed 12.5% 30.7% the U.S. and Western Europe ● All growth platforms delivered USA 27.8% double-
Slide 12: Consumer Health Care - Doubled Sales in only 2 Years
12 Consumer Health Care - Doubled Sales in only 2 Years ● Q1 2011 sales: €712m, +40.3% at CER ● CHC driven by organic growth(1) ● Allegra® OTC successfully and acquisitions in the U.S. and launched in the U.S. in March China ● Q1 2011 sales: €80m Q1 Sales (€m) €712m ● Outselling Zyrtec OTC as early
Slide 13: Generics - An Additional Key Growth Driver
13 Generics - An Additional Key Growth Driver ● Q1 2011 sales: €414m, Q1 Sales (€m) +16.9% at CER €414m Others ● Authorized generics of €343m Ambien® CR and Taxotere® launched in the U.S. Emerging ● : 3rd largest player(1) Markets and among fastest growing generic companies in Europe ● : leader in B
Slide 14: Diabetes - Back to Double-Digit Growth in Q1 2011
Diabetes - Back to Double-Digit Growth in 14 Q1 2011 Q1 Sales(1) ● Q1 2011 sales: €925m, +13.2% at +31.4% Others Emerging CER Markets +19.1% ● Reacceleration of growth in the Western EU U.S. following increase in Share of +1.2% Voice ● Stable EU sales: volume growth counter-balanced price cuts +14.7
Slide 15: Vaccines – Good Start to the Year
15 Vaccines – Good Start to the Year Vaccines Consolidated Sales (€m) ● Q1 2011 Sales: €602m, +9.6% at CER excluding A/H1N1(1) A/H1N1 ● Strong Emerging Markets sales of €413m €602m €282m, +37.1% at CER excluding A/H1N1, driven by: ● Record seasonal flu campaign ● Solid growth of ● Good performance o
Slide 16: New Products - €111m in Q1 2011
16 New Products - €111m in Q1 2011 ● Q1 2011 sales: €48m Q1 Sales (€m) ● 54% share of U.S. patients in 2L mHRPC(1) €111m ● EC approval on March 18, 2011 ● Launch in Germany in April ● Most EU countries expected to launch before ® 48 the end of 2011 ® ● Q1 2011 sales: €63m 63 ● Revised label ● Two ne
Slide 17: Some Green Shoots in Late-Stage Development
17 Some Green Shoots in Late-Stage Development ZALTRAP® Multiple milestones over next 12 months
Slide 18: Investing in Sustainable Growth
18 Investing in Sustainable Growth ● Strong double-digit sales growth of our growth platforms(1) ● On-track to deliver cost savings of €2.0bn by end of 2011(2) ● Limited erosion of Business EPS excluding impact of A/H1N1 and Copaxone® ● Strong free cash flow generation lead to net debt free status a